Table 3 Additional analysis; adjusted Third Dose Effectiveness (VE) against SARS-Cov2 infection, compared to second-dose only vaccinees.

From: Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine

Exposure Groups/Booster Period

Cases

Controls

Adjusted Third Dose VE (%) for SARS-Cov2 Infection (CI 95%)

Second Dose Only

7866

6264

Reference

August 2021 (−5)‡

21,900

21,588

16 (12.3, 19.5)

September 2021 (−4)‡

25,920

25,623

18.3 (15.2, 21.2)

October 2021 (−3)‡

7378

8583

29.1 (26.1, 32)

November 2021 (−2)‡

872

1305

43.2 (38.2, 47.8)

December 2021 (−1)‡

491

1064

59.4 (54.9, 63.5)

 

64,427

64,427

 
  1. ‡ Denotes the months prior to the outcome period. Therefore, those who received the booster in October 2021, received the third dose 3 months prior to the outcome period.
Back to article page